ArticleThe oncologist2015
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04790708 (Peptide Receptor Radionuclide Therapy), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors
Who cites it
4 citing papers in PubMed.
- Solid pancreatic masses in children: A review of current evidence and clinical challenges.Frontiers in pediatrics · 2022Review
- Review
- The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.Journal of thoracic disease · 2017Review
- Refractory carcinoid syndrome: a review of treatment options.Therapeutic advances in medical oncology · 2017Review
Corrections and comments
- Erratum for
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.